MPT WWW
Selected news articles which highlight important policy issues.

News: Weekly Archives

News for the week of 01-28-2007

FDA Reforms Seek Right Dose
Winston-Salem Journal, 1-28-07

Editor's Notes:

This article highlights a 1997 FDA reform that speeded patient access to important new treatments for serious and life–threatening diseases—a welcome reflection on the importance of drug access at a time when many critics have taken the FDA to task for approving products too quickly.

Revlimid can't cure Alice Duggins, but it can buy her time. Duggins has a blood disorder that can lead to leukemia, and while she waits for a bone–marrow transplant, Revlimid boosts her red–blood–cell count. Not even blood transfusions would help, said Duggins, who lives in Walnut Cove. "It would be like putting gas in a tank that has a hole in it."

Revlimid is among a number of drugs that have gotten fast–track approval from the Food and Drug Administration under a law sponsored by Sen. Richard Burr 10 years ago, when he was a member of the House of Representatives. Among other things, the bill gave drug companies a way to get some critically needed drugs to the head of the line for approval and lifted certain marketing restrictions on off–label uses of drugs already approved.

The FDA has reduced the time it takes to approve new drugs, but the number of approvals hasn't increased significantly. "This is absolutely a better process than it was," said Bayard Powell, the chief of the hematology and oncology section at Wake Forest University Baptist Medical Center. The reforms have been particularly important for cancer patients, Powell said.

No law is perfect, Burr said, but he thinks that the FDA modernization has been a success. Later this year, Congress is expected to take up its five–year reauthorization of the law, giving legislators a look at its strengths and weaknesses and its critics a chance to push for changes.

The reauthorization is taking place at a time when pharmaceutical companies are both powerful and vulnerable and prescription drugs are more important than ever to health insurance and consumers.

[permanent link]



Project FDA.

2007-06-11
2007-06-07
2007-05-28
2007-05-23
2007-04-26
2007-04-18
2007-04-13
2007-04-05
2007-03-30
2007-03-12
2007-03-08
2007-03-01
2007-02-21
2007-02-14
2007-01-31
2007-01-28
2007-01-18
2007-01-11
2007-01-02
2006-12-29
2006-12-20
2006-12-12
2006-12-04
2006-11-27
2006-11-26
2006-11-13
2006-11-06
2006-11-01
2006-10-24
2006-10-19
2006-10-10
2006-10-06
2006-09-25
2006-09-23
2006-09-13
2006-08-30
2006-08-23
2006-08-14
2006-08-10
2006-08-03
2006-07-26
2006-07-18
2006-07-10
2006-07-06
2006-06-30
2006-06-22
2006-06-15
2006-06-08
2006-06-02
2006-05-23
2006-05-19
2006-05-08
2006-05-01
2006-04-19
2006-04-12
2006-02-14
2006-02-09
2006-02-01
2006-01-24
2006-01-19
2006-01-10
2006-01-04
2005-12-29
2005-12-21
2005-12-13
2005-12-06
2005-11-30
2005-11-22
2005-11-17
2005-11-09
2005-11-02
2005-10-26
2005-10-19
2005-10-12
2005-10-05
2005-09-28
2005-09-21
2005-09-14
2005-09-05
2005-08-29
2005-08-23
2005-08-16
2005-08-09
2005-08-04
2005-07-27
2005-07-20
2005-07-11
2005-07-06
2005-07-01
2005-06-13
2005-06-09
2005-06-05
2005-05-25
2005-05-18
2005-05-10
2005-05-02
2005-04-27
2005-04-20
2005-04-11
2005-04-05
2005-03-30
2005-03-21
2005-03-18
2005-03-08
2005-03-01
2005-02-23
2005-02-14
2005-02-07
2005-01-31
2005-01-24
2005-01-17
2005-01-10
2005-01-04
2004-12-31
2004-12-21
2004-12-13
2004-12-06
2004-11-29
2004-11-22
2004-11-15
2004-11-10
2004-11-01
2004-10-28
2004-10-19
2004-10-11
2004-10-05
2004-09-29
2004-09-21
2004-09-15
2004-09-08
2004-08-30
2004-08-25
2004-08-16
2004-08-09
2004-08-03
2004-07-26
2004-07-19
2004-07-12
2004-07-05
2004-06-29
2004-06-21
2004-06-14
2004-06-08
2004-06-01
2004-05-24
2004-05-17
2004-05-10
2004-05-02
0206-12-04
0000-00-00

  
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org